Blair William & Co. IL Reduces Stock Position in Inspire Medical Systems, Inc. (NYSE:INSP)

Blair William & Co. IL decreased its stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 42.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,816 shares of the company's stock after selling 3,501 shares during the quarter. Blair William & Co. IL's holdings in Inspire Medical Systems were worth $893,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. First Horizon Advisors Inc. raised its holdings in shares of Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock worth $26,000 after buying an additional 124 shares during the last quarter. Harbour Investments Inc. boosted its position in shares of Inspire Medical Systems by 101.0% during the 4th quarter. Harbour Investments Inc. now owns 197 shares of the company's stock valued at $37,000 after acquiring an additional 99 shares during the last quarter. AlphaQuest LLC lifted its stake in shares of Inspire Medical Systems by 7,275.0% in the 4th quarter. AlphaQuest LLC now owns 295 shares of the company's stock valued at $55,000 after purchasing an additional 291 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Inspire Medical Systems by 178.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 357 shares of the company's stock worth $66,000 after purchasing an additional 229 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its position in shares of Inspire Medical Systems by 37.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 368 shares of the company's stock worth $68,000 after acquiring an additional 100 shares during the period. 94.91% of the stock is currently owned by institutional investors.

Remove Ads

Inspire Medical Systems Price Performance

Shares of INSP traded down $8.06 during mid-day trading on Tuesday, reaching $141.63. 576,356 shares of the company's stock were exchanged, compared to its average volume of 591,982. The business's fifty day simple moving average is $173.26 and its 200-day simple moving average is $186.81. The stock has a market capitalization of $4.21 billion, a PE ratio of 81.86, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39. Inspire Medical Systems, Inc. has a 52-week low of $123.00 and a 52-week high of $257.40.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. Equities research analysts predict that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, insider Randy Ban sold 25,584 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the sale, the insider now directly owns 7,259 shares in the company, valued at approximately $1,332,026.50. The trade was a 77.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO John Rondoni sold 583 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.30% of the company's stock.

Wall Street Analyst Weigh In

INSP has been the subject of several recent research reports. Piper Sandler decreased their price objective on Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Stifel Nicolaus decreased their price target on shares of Inspire Medical Systems from $200.00 to $190.00 and set a "hold" rating for the company in a research note on Tuesday, January 21st. Wells Fargo & Company dropped their price objective on shares of Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. Robert W. Baird dropped their target price on Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating on the stock in a report on Tuesday, February 11th. Finally, KeyCorp reaffirmed an "overweight" rating and set a $234.00 price target (down from $236.00) on shares of Inspire Medical Systems in a report on Friday, January 24th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $226.70.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.